| SKU | ISG007741 |
| Brand | Xigduo |
| Categories | Medication & Treatments |
| Concentrations | 5 Mg |
| Shop by Concerns | Cardiovascular Risk Factors |
| Gender | Neutral |
| Shop By Goals | Diabetes Management |
| Imported Or Local | Local |
| Ingredient | Dapagliflozin Metformin hydrochloride |
| Specialty | Clinically Tested Dual Action Glucose Control Prescription only |
| Sub Categories | Insulin And Diabetic Medicines |
| Warning | Avoid in severe renal impairment Not for Type 1 Diabetes or Ketoacidosis Use under medical supervision Risk of Lactic Acidosis Risk of genital and urinary infections |
Xigduo 5 Mg
Description:
Xigduo 5/1000 mg film‑coated tablets is a prescription oral antidiabetic medicine that combines two active ingredients: dapagliflozin and metformin. It is used as part of a comprehensive type 2 diabetes management plan that includes a healthy diet, regular physical activity, and lifestyle modification. Xigduo helps lower high blood sugar (hyperglycemia), improve glycemic control, and reduce the risk of diabetes‑related complications in adults with type 2 diabetes mellitus. It belongs to the sodium‑glucose co‑transporter 2 (SGLT2) inhibitor class (dapagliflozin) and biguanide class (metformin), offering dual and complementary mechanisms of action for better blood glucose control.
Indications:
- Type 2 diabetes mellitus in adults as an adjunct to diet and exercise to improve glycemic control.
- May be used in patients insufficiently controlled on metformin alone or already treated with the combination of dapagliflozin and metformin as separate tablets.
- Helps reduce fasting and post‑prandial (after meal) blood glucose levels.
- Helps lower the risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors (as per clinical use of dapagliflozin‑containing regimens).
- Assists in preventing long‑term complications of uncontrolled diabetes such as kidney damage (diabetic nephropathy), eye damage (diabetic retinopathy), nerve damage (neuropathy), and cardiovascular events when used as part of an overall diabetes care plan.
Active Ingredients / Key Components:
- Dapagliflozin – 5 mg per film‑coated tablet (SGLT2 inhibitor).
- Metformin hydrochloride – 1000 mg per film‑coated tablet (biguanide).
- Other excipients (film‑coating agents, fillers, binders, etc.) are present but detailed composition is not available in the provided information. Please refer to the official package leaflet for the full excipient list.
Dosage & Administration / How to Use:
- Use exactly as prescribed by your physician. Do not change your dose or stop taking the medicine without medical advice.
- Typical adult dose: Xigduo 5/1000 mg is usually taken twice daily (morning and evening), but the exact regimen, total daily dose, and duration are determined individually by the treating doctor based on previous therapy, kidney function, and blood glucose targets.
- Administration: Take the tablets orally with meals to reduce gastrointestinal side effects associated with metformin (such as nausea and stomach upset).
- Swallow the tablet whole with a glass of water. Do not crush, break, or chew the film‑coated tablet unless your doctor or pharmacist specifically instructs otherwise.
- If you miss a dose, take it as soon as you remember unless it is almost time for your next dose. Do not double the dose to make up for a missed dose.
- Regular monitoring of blood glucose, HbA1c, kidney function, and overall clinical status is recommended during treatment.
- Use in children: Safety and efficacy in pediatric patients have not been established; this product is generally intended for adults only unless otherwise directed by a specialist.
Clinical Benefits:
- Provides dual glucose‑lowering action by reducing glucose production in the liver (metformin) and increasing urinary glucose excretion via the kidneys (dapagliflozin).
- Helps improve overall glycemic control, including fasting plasma glucose and post‑meal blood sugar levels, when used with diet and exercise.
- Supports long‑term reduction in the risk of diabetes‑related complications such as kidney damage, eye disease, nerve damage, and cardiovascular events when blood sugar is well controlled.
- May contribute to modest weight reduction and lower blood pressure in some patients due to dapagliflozin’s mechanism of increasing glucose and sodium excretion in urine.
- Offers convenient fixed‑dose combination therapy, reducing pill burden compared with taking dapagliflozin and metformin separately.
Warnings & Contraindications:
- Contraindicated in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
- Contraindicated in patients with severe renal impairment, end‑stage renal disease, or on dialysis (due to metformin accumulation and risk of lactic acidosis, and reduced efficacy of dapagliflozin).
- Do not use in patients with known hypersensitivity or allergy to dapagliflozin, metformin, or any of the excipients.
- Risk of lactic acidosis: Metformin can rarely cause a serious, potentially fatal condition called lactic acidosis, especially in patients with significant kidney impairment, severe infection, dehydration, liver disease, excessive alcohol intake, or conditions associated with hypoxia (e.g., heart failure, recent myocardial infarction, respiratory failure). Seek urgent medical help if you develop unexplained weakness, muscle pain, breathing difficulty, abdominal pain, or unusual drowsiness.
- Risk of volume depletion and low blood pressure: Dapagliflozin increases urinary glucose and fluid loss. Use with caution in elderly patients, those on diuretics, or with low blood pressure, and ensure adequate fluid intake.
- May increase the risk of genital mycotic (fungal) infections and urinary tract infections due to higher glucose in urine.
- Temporary discontinuation may be required before major surgery or imaging procedures with iodinated contrast media to reduce the risk of lactic acidosis; follow your doctor’s instructions.
- Use with caution in patients with liver disease, heart failure, recurrent urinary tract infections, or a history of ketoacidosis.
- Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding. Alternative treatments may be preferred during pregnancy and lactation.
- Hypoglycemia risk increases when used together with insulin or insulin secretagogues (e.g., sulfonylureas); dose adjustment of these agents may be required.
- Avoid excessive alcohol consumption while taking metformin‑containing products due to increased risk of lactic acidosis.
- Not intended to diagnose, treat, cure, or prevent any disease without medical supervision; it is a prescription medicine that must be used under a doctor’s care.
- Keep out of reach of children.
Side Effects:
- Common side effects: Genital yeast infections (especially in women), urinary tract infections, increased urination, nausea, vomiting, diarrhea, abdominal discomfort, loss of appetite, headache, and mild dehydration symptoms (thirst, dry mouth).
- Metformin‑related gastrointestinal symptoms are more likely at the start of therapy and often improve over time; taking the medicine with food can help.
- Possible decreases in blood pressure, especially in patients on diuretics or with low baseline blood pressure.
- Less common but serious side effects: Lactic acidosis (rare but potentially life‑threatening), severe dehydration, acute kidney injury, severe urinary tract infections, Fournier’s gangrene (a rare but serious infection of the genital area), and ketoacidosis (even with relatively normal blood glucose levels).
- Seek immediate medical attention if you experience signs of lactic acidosis (rapid breathing, severe weakness, unusual muscle pain, stomach pain with nausea/vomiting, feeling very cold or dizzy), signs of severe infection (high fever, pain, burning urination, flank pain), or symptoms of ketoacidosis (nausea, vomiting, abdominal pain, confusion, unusual fatigue, difficulty breathing).
- If any side effect persists, worsens, or you notice any other unusual symptoms, contact your doctor or pharmacist promptly.
Storage Instructions:
Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children.
Specifications:
- Product form: Film‑coated tablets for oral use.
- Strength per tablet: dapagliflozin 5 mg + metformin hydrochloride 1000 mg.
- Pack size: 56 film‑coated tablets (sufficient for several weeks of therapy depending on prescribed dose).
- Intended use: Prescription antidiabetic medicine for adults with type 2 diabetes mellitus.
Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.
